Abstract: The invention provides pellet for use as a core for a pharmaceutical dosage form having an inner and an outer zone where the inner zone includes a biologically active agent and said outer zone includes a layer formed by applying a substantially dry, free flowing inert powder which forms a non-tacky surface when placed in contact with water. The invention also provides a process for making pharmaceutical pellets where the core or at least one a layer on the core is formed by (a) contacting powder particles, adhering them to each other and compacting the adhered pellets by a rolling movement, wherein the degree of densification is controlled by the rolling movement; and (b) feeding a sufficient amount of a substantially dry, free flowing inert powder which forms a non-tacky surface when placed in contact with water to provide on said particles an outer zone including a layer formed from said substantially dry, free flowing inert powder.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: The invention relates to picolinamides of Formula I and their use as fungicides.

Abstract: A portable consumer device, such as a mobile phone or a tablet computer, may be configured to collect measurements data associated with at least one of movement of the portable consumer device or orientation of the portable consumer device, as well as data associated with an external environment of the portable consumer device. The collected data may be evaluated in order to determine motion of the portable consumer device over time and contextual information associated with the portable consumer device. A user activity may be determined based upon the determined motion and the determined contextual information. As desired, the user activity may be evaluated in association with a suitable application scenario, such as a gaming application scenario.

Abstract: This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides.

Abstract: This disclosure relates to macrocyclic picolinamides of Formula I and their use as fungicides.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: The invention relates to picolinamides of Formula I and their use as fungicides.

Abstract: A releasable vest having a front panel; front shoulder strap elements that include at least one front shoulder strap attachment opening; a back panel; a first waist belt element and a second waist belt element that are releasably coupled to the front panel and extend from the front panel; at least one release loop that is capable of being passed through an opening formed in at least one of the waist belt elements and an opening formed in the front shoulder strap elements; and a release lanyard that is capable of being passed through the release loop so as to releasably secure the waist belt elements and the shoulder strap elements to the release loop.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: This disclosure relates to picolinamides of Formula I and their use as fungicides.

Abstract: A compressed tablet of a pharmaceutical compound which contains uncoated pellets containing a pharmaceutical compound, where the uncoated pellets are dispersed in a matrix containing the pellets and a swellable polymer.

Abstract: Described herein are methods of generating a protein binding domain that specifically binds to gp120 in a specific conformational state, comprising contacting gp120 with a CD4-mimetic compound, thereby forming gp120 in the specific conformational state; and generating antibodies to gp120 in the specific conformation state. Relatedly, the disclosure also describes methods of neutralizing HIV-1, comprising contacting HIV-1 with an effective amount of a CD4-mimetic compound, thereby forming HIV-1 having gp120 in a specific conformational state; and contacting the HIV-1 in the specific conformational state with an antibody.